Trials to treat overcorrected myopia:
This article was originally published in Clinica
The FDA has given conditional approval to begin a study using Sunrise Technologies' LTK system to treat patients with induced hyperopia after overcorrection from excimer laser treatment for myopia. Theoretically, under 5% of myopic laser treatments carried out by experienced excimer laser operators result in overcorrection. However, an incidence of up to 50% has been recorded amongst less experienced operators. Studies performed outside the US have shown that LTK can correct induced hyperopia with minimal trauma to the patient. VISX and Summit market the only approved photorefractive keratectomy lasers (see front page).
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.